Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Co-treatment with yoga plus camelina sativa powder improves outcomes in women with T2D

10 Jul 2026

In women with type 2 diabetes (T2D), performing yoga in addition to supplementation with camelina sativa powder (CSP) delivers improvements in glycaemic indices, oxidative stress, and inflammatory markers, according to a study.

Co-treatment with yoga plus camelina sativa powder improves outcomes in women with T2D

10 Jul 2026

Okra supplementation may lower cardiovascular risk in prediabetes, T2D, diabetic nephropathy

10 Jul 2026

Okra supplementation is beneficial to patients with prediabetes, type 2 diabetes (T2D), or diabetic nephropathy, conferring beneficial effects on lipid profile, diastolic BP, and inflammation markers, according to a systematic review and meta-analysis.

Okra supplementation may lower cardiovascular risk in prediabetes, T2D, diabetic nephropathy

10 Jul 2026

Is wine safe for people with diabetes?

09 Jul 2026 bởi

Drinking wine in moderation may lower the risk of developing type 2 diabetes (T2D) and even yield some cardiovascular benefits in people with T2D, suggests a study.

Is wine safe for people with diabetes?

09 Jul 2026

Original New Drug Application Approvals by US FDA (16-30 June 2026)

09 Jul 2026

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2026)

09 Jul 2026

Consistent resistance training, limited sedentary behaviour help lower T2D risk

08 Jul 2026

Engaging in resistance training over midlife and limiting sedentary behaviour have been shown to substantially lower the risk of type 2 diabetes (T2D) in a study.

Consistent resistance training, limited sedentary behaviour help lower T2D risk

08 Jul 2026

Triple win for fixed-dose combo in T2D

08 Jul 2026 bởi

A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA_1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.

Triple win for fixed-dose combo in T2D

08 Jul 2026

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026 bởi

The overall development of vision-threatening diabetic retinopathy (DR) among Asians with diabetes is low, although the incidence of progression to vision-threatening disease for those who already have DR is high, according to local research.

Low vision-threatening DR incidence contrasts with high progression rate among Asians

07 Jul 2026

CGM plus virtual program improves HbA1c, weight in T2D adults with overweight/obesity

05 Jul 2026

Continuous glucose monitoring (CGM) combined with a digital weight management program results in significant improvements in HbA1c, body weight, and other glucose metrics relative to usual care among adults with type 2 diabetes (T2D) and overweight or obesity, according to a study.

CGM plus virtual program improves HbA1c, weight in T2D adults with overweight/obesity

05 Jul 2026

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

A recent study suggests that time-restricted eating (TRE) may help reduce weight and improve cardiometabolic health by regulating gut microbiota and serum metabolites.

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

In patients with stable inflammatory bowel disease (IBD) receiving advanced therapies who have comorbid obesity and/or diabetes, adjunctive treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide or tirzepatide does not appear to improve clinical outcomes, according to new research.

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

Tin tức & Cập nhật

Xem bài viết Nội tiết

Xem

Chuyên ngành:

Co-treatment with yoga plus camelina sativa powder improves outcomes in women with T2D

Co-treatment with yoga plus camelina sativa powder improves outcomes in women with T2D

Okra supplementation may lower cardiovascular risk in prediabetes, T2D, diabetic nephropathy

Okra supplementation may lower cardiovascular risk in prediabetes, T2D, diabetic nephropathy

Is wine safe for people with diabetes?

Is wine safe for people with diabetes?

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Triple win for fixed-dose combo in T2D

Triple win for fixed-dose combo in T2D

Low vision-threatening DR incidence contrasts with high progression rate among Asians

Low vision-threatening DR incidence contrasts with high progression rate among Asians

CGM plus virtual program improves HbA1c, weight in T2D adults with overweight/obesity

CGM plus virtual program improves HbA1c, weight in T2D adults with overweight/obesity

Time-restricted eating reshapes gut microbiota to induce weight loss

Time-restricted eating reshapes gut microbiota to induce weight loss

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes